Notwithstanding the new EULAR/ACR criteria and the aforementioned pathological correlations, the clinical use and significance of ANAs and anti-DNA in SLE patients is increasingly challenged by recent clinical trials and experiments, revealing high percentages of SLE patients with negative ANA (15–17). Here, BTG3 is linked to systemic lupus erythematosus.